Lilly’s Foundayo Lags with 3,707 Prescriptions, Shares Drop 2.6%
Foundayo generated 3,707 second-week prescriptions, versus 18,410 for oral Wegovy, driving Eli Lilly shares down 2.6%. Analysts warn true uptake assessment will take two to three months due to sampling and telehealth challenges.
1. Early Prescription Data
Foundayo recorded 3,707 prescriptions in its second week, markedly below the 18,410 scripts seen by Novo Nordisk’s oral Wegovy over the same launch period.
2. Market Reaction
Eli Lilly shares declined 2.6% following the data release as investors weighed the slower-than-expected pill uptake against high market expectations.
3. Assessment Challenges
Analysts caution that sampling programs and the difficulty of capturing telehealth prescriptions mean meaningful performance analysis will require two to three months of data.
4. Competitive Positioning
Despite Foundayo’s more flexible dosing restrictions, trial comparisons indicate it delivers less weight loss than the semaglutide-based Wegovy pill, reinforcing Novo’s early lead.